|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Alirocumab significantly reduced other lipid/lipoproteins (including lipoprotein[a]) similarly in patients with/without MI/ischemic stroke.
|
31076261 |
2020 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] levels predict the risk of myocardial infarction (MI) in populations of European ancestry; however, few data are available for other ethnic groups.
|
30667276 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Further, in 108,602 individuals from the Copenhagen General Population Study in random nonfasting samples, the highest versus the lowest quartile of triglycerides, total cholesterol, LDL cholesterol, remnant cholesterol, non-HDL cholesterol, lipoprotein(a), and apolipoprotein B were all associated with higher risk of both ischaemic heart disease and myocardial infarction.
|
30522787 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
High lipoprotein(a) is associated with increased risk of myocardial infarction and aortic valve stenosis.
|
31272552 |
2019 |
|
Myocardial Infarction
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
High lipoprotein(a) levels are observationally and causally, from human genetics, associated with increased risk of cardiovascular disease including myocardial infarction and aortic valve stenosis.
|
31111240 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
A total of 538 proteins are quantified, with pregnancy zone protein (PZP), leucine-rich α-2-glycoprotein (LRG) and Apolipoprotein C-I (Apo C-I) being upregulated and Apolipoprotein A-I (Apo A-I) and Apolipoprotein A-IV (Apo A-IV) downregulated in early-onset MI patients.
|
30411527 |
2019 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction.
|
29883631 |
2018 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
APOE ε2 is a strong genetic determinant of low lipoprotein(a) concentrations but does not modify the causal association of lipoprotein(a) with myocardial infarction or aortic valve stenosis.
|
28651346 |
2017 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We found that individuals with HDL-C ≤1.25 mmol/L, GRS >20.9 and lipoprotein (a) > 0.09 g/L had a higher risk of MI than those who at the lowest risk group (OR: 5.89, 95% CI: 3.99-8.69).
|
29258680 |
2017 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is the strongest independent genetic risk factor for both myocardial infarction and aortic stenosis.
|
28059953 |
2017 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).
|
28838919 |
2017 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
In participants for whom KIV2 repeat and lipoprotein(a) data were available, the OR for myocardial infarction was 0·93 (95% CI 0·90-0·97; p<0·0001) per 1-SD increment in LPA KIV2 repeats after adjustment for lipoprotein(a) concentration and conventional lipid concentrations.
|
28408323 |
2017 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We tested the hypotheses that high lipoprotein(a) cholesterol and LPA risk genotypes are a possible cause of clinical familial hypercholesterolaemia, and that individuals with both high lipoprotein(a) concentrations and clinical familial hypercholesterolaemia have the highest risk of myocardial infarction.
|
27185354 |
2016 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Elevated lipoprotein(a) levels represent a genetically determined risk factor for myocardial infarction (MI) and aortic valve stenosis (AVS).
|
26656145 |
2016 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a), LDL cholesterol, and PCSK9 R46L genotype and diagnoses of aortic valve stenosis and myocardial infarction from national registries; lipoprotein(a) was measured from 49,617 individuals.
|
27218270 |
2016 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Human epidemiologic and genetic evidence using the Mendelian randomization approach in large-scale studies now strongly supports that elevated lipoprotein (a) [Lp(a)] is a causal risk factor for cardiovascular disease, that is, for myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis.
|
27677946 |
2016 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
There were two serious adverse events (myocardial infarctions) in the IONIS-APO(a)<sub>Rx</sub> phase 2 trial, one in the IONIS-APO(a)<sub>Rx</sub> and one in the placebo group, but neither were thought to be treatment related.
|
27665230 |
2016 |
|
Myocardial Infarction
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of lipoprotein(a) were not causally associated with increased low-grade inflammation as measured through CRP despite a causal association with increased risk of aortic valve stenosis and MI.
|
25938632 |
2015 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.
|
26343387 |
2015 |
|
Myocardial Infarction
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
As some incorrect reclassification of individuals with no events occurred, addition of lipoprotein(a) levels ≥80th percentile overall yielded net reclassification indices of +16% (95% confidence interval: 8% to 24%) and +3% (-1% to 8%) for MI and CHD, respectively.
|
23375930 |
2013 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Lp(a) and LPA kringle IV type 2 tertiles also associated with the risk of myocardial infarction in general population studies (trend: P<0.001 to 0.003).
|
22516069 |
2012 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) concentration does not differ between sexes in healthy offspring of patients with premature myocardial infarction.
|
21519277 |
2011 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) (Lp(a)) is an important causal cardiovascular risk factor, with serum Lp(a) levels predicting atherosclerotic heart disease and genetic determinants of Lp(a) levels showing association with myocardial infarction.
|
21283670 |
2011 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The association of LPA KIV-2 genotypes raising plasma levels of lipoprotein(a) with increased risk of myocardial infarction strongly supports a causal association of lipoprotein(a) with risk of myocardial infarction.
|
21231777 |
2011 |
|
Myocardial Infarction
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In the CCHS, multivariable-adjusted hazard ratios (HRs) for MI for elevated lipoprotein(a) levels were 1.2 (95% confidence interval [CI], 0.9-1.6; events/10,000 person-years, 59) for levels between the 22nd and 66th percentile, 1.6 (95% CI, 1.1-2.2; events/10,000 person-years, 75) for the 67th to 89th percentile, 1.9 (95% CI, 1.2-3.0; events/10,000 person-years, 84) for the 90th to 95th percentile, and 2.6 (95% CI, 1.6-4.1; events/10,000 person-years, 108) for levels greater than the 95th percentile, respectively, vs levels less than the 22nd percentile (events/10,000 person-years, 55) (trend P < .001).
|
19509380 |
2009 |